Fehér J, Kiss A, Blazovics A, Szondy E, Toncsev H, Mathiász D, Gerö S
Drugs Exp Clin Res. 1985;11(6):413-9.
The antiatherosclerotic profile of nicotinic acid and of its new water-insoluble derivative was studied in an 8-day experiment in rats. Both drugs lowered plasma triglyceride levels significantly, while other lipoprotein parameters were unaffected. Circulating immune complex levels were decreased with lysosomal membrane permeability by both drugs. Glunicate proved to be a powerful antioxidant with regard to enzymatic lipid peroxidation when studied in the liver microsomal system. The relevance of these findings to the antiatherosclerotic effect of the drugs and the biological significance of antioxidant treatment is discussed. On the basis of these data glunicate seems to be a promising new therapeutic tool against atherosclerosis and merits further study.
在一项为期8天的大鼠实验中,研究了烟酸及其新的水不溶性衍生物的抗动脉粥样硬化特性。两种药物均显著降低了血浆甘油三酯水平,而其他脂蛋白参数未受影响。两种药物均通过降低溶酶体膜通透性来降低循环免疫复合物水平。在肝脏微粒体系统中进行研究时,戊四烟酯被证明是一种对酶促脂质过氧化具有强大抗氧化作用的物质。讨论了这些发现与药物抗动脉粥样硬化作用的相关性以及抗氧化治疗的生物学意义。基于这些数据,戊四烟酯似乎是一种有前景的抗动脉粥样硬化新治疗工具,值得进一步研究。